TRINITY OF SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS-2: ORIGIN, GENOTYPE, PHENOTYPE, AND IMMUNE RESPONSE IN CORONAVIRUS DISEASE-2019

Authors

  • MURUGAN NANDAGOPAL Molecular Testing-Infectious Disease Division, Life Cell International Pvt Ltd., Chennai, Tamil Nadu, India.
  • ARULMOZHI BALAKRISHNAN Department of Microbiology, University of Madras, IBMS, Chennai, Tamil Nadu, India.
  • CHIRAYU PADHIAR Molecular Testing-Infectious Disease Division, Life Cell International Pvt Ltd., Chennai, Tamil Nadu, India.

DOI:

https://doi.org/10.22159/ajpcr.2021.v14i9.42363

Keywords:

Severe acute respiratory syndrome coronavirus-2, Coronavirus disease-2019, Genomic Origin, Pathogenesis, Immunity

Abstract

The coronavirus disease-2019 (COVID-19) outbreak by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) or a novel coronavirus (2019-CoV) has prompted global health concerns. A pandemic resulted from the disease’s transmission through many routes. In this pandemic, the interaction between coronavirus and the host immune system, particularly the innate immune system, is becoming more prominent. Against viruses and pathogens, innate immunity serves as a first line of defense. Our understanding of pathogenesis will benefit from a better grasp of the mechanisms of immune evasion techniques. The origin, classification, structure, and method of transmission of SARS-CoV-2 were summarized in this paper. We have discussed the importance of important communications. In this review, we have discussed the function of important components of the innate immune system in COVID-19 infection, as well as how the virus evades innate immunity through multiple tactics and contributes to a wide range of clinical symptoms and outcomes.

Downloads

Download data is not yet available.

Author Biography

MURUGAN NANDAGOPAL, Molecular Testing-Infectious Disease Division, Life Cell International Pvt Ltd., Chennai, Tamil Nadu, India.

Scientist & Manager, Lifecell Private International, Chennai, India.

Postdoctoral Research Scientist, Wayne State University, Michigan, United States of America.

Associate Scientist, MEDGENOME LABS PVT LTD., & ADJUNCT FACULTY, SANKARA NETHRALAYA, CHENNAI

References

Hosseini A, Hashemi V, Shomali N, Asghari F, Gharibi T, Akbari M, et al. Innate and adaptive immune responses against coronavirus. Biomed Pharmacother 2020;132:110859.

Ouassou H, Kharchoufa L, Bouhrim M, Daoudi NE, Imtara H, Bencheikh N, et al. The pathogenesis of coronavirus disease 2019 (COVID-19): Evaluation and prevention. J Immunol Res 2020;2020:1357983.

Birra D, Benucci M, Landolfi L, Merchionda A, Loi G, Amato P, et al. COVID 19: A clue from innate immunity. Immunol Res 2020;68:161-8.

Mavrodiev EV, Tursky ML, Mavrodiev NE, Ebach MC, Williams DM. On classification and taxonomy of coronaviruses (Riboviria, Nidovirales, Coronaviridae) with special focus on severe acute respiratory syndrome-related coronavirus 2 (SARS-Cov-2). BioRxiv 2020.

Lefkowitz EJ, Dempsey DM, Hendrickson RC, Orton RJ, Siddell SG, Smith DB. Virus taxonomy: The database of the international committee on taxonomy of viruses (ICTV). Nucleic Acids Res 2018;46:D708-17.

Shereen MA, Khan S, Kazmi A, Bashir N, Siddique R. COVID-19 infection: Origin, transmission, and characteristics of human coronaviruses. J Adv Res 2020;24:91.

Chan JF, Kok KH, Zhu Z, Chu H, To KK, Yuan S, et al. Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan. Emerg Microbes Infect 2020;9:221-36.

Rahman HS, Aziz MS, Hussein RH, Othman HH, Omer SH, Khalid ES, et al. The transmission modes and sources of COVID-19: A systematic review. Int J Surg Open 2020;26:125-36.

Tran K, Cimon K, Severn M, Pessoa-Silva CL, Conly J. Aerosol generating procedures and risk of transmission of acute respiratory infections to healthcare workers: A systematic review. PLoS One 2012;7:e35797.

Guo YR, Cao QD, Hong ZS, Tan YY, Chen SD, Jin HJ, et al. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak-an update on the status. Mil Med Res 2020;7:1-10.

Mirzaei R, Karampoor S, Sholeh M, Moradi P, Ranjbar R, Ghasemi F. A contemporary review on pathogenesis and immunity of COVID-19 infection. Mol Biol Rep 2020;47:5365-76.

Liang Y, Wang ML, Chien CS, Yarmishyn AA, Yang YP, Lai WY, et al. Highlight of immune pathogenic response and hematopathologic effect in SARS-CoV, MERS-CoV, and SARS-Cov-2 infection. Front Immunol 2020;11:1022.

Mousavizadeh L, Ghasemi S. Genotype and phenotype of COVID-19: Their roles in pathogenesis. J Microbiol Immunol Infect 2020;54:159-63.

Weiss SR, Leibowitz JL. Coronavirus pathogenesis. Adv Virus Res 2011;81:85-164.

Skariyachan S, Challapilli SB, Packirisamy S, Kumargowda ST, Sridhar VS. Recent aspects on the pathogenesis mechanism, animal models and novel therapeutic interventions for Middle East respiratory syndrome coronavirus infections. Front Microbiol 2019;10:569.

Satarker S, Nampoothiri M. Structural proteins in severe acute respiratory syndrome coronavirus-2. Arch Med Res 2020;51:482-91.

Woo PC, Huang Y, Lau SK, Yuen KY. Coronavirus genomics and bioinformatics analysis. Viruses 2010;2:1804-20.

Fehr AR, Perlman S. Coronaviruses: An overview of their replication and pathogenesis. Coronaviruses 2015;1282:1-23.

DeDiego ML, Alvarez E, Almazán F, Rejas MT, Lamirande E, Roberts A, et al. A severe acute respiratory syndrome coronavirus that lacks the E gene is attenuated in vitro and in vivo. J Virol 2007;81:1701-13.

Nieto-Torres JL, DeDiego ML, Verdiá-Báguena C, Jimenez-Guardeño JM, Regla-Nava JA, Fernandez-Delgado R, et al. Severe acute respiratory syndrome coronavirus envelope protein ion channel activity promotes virus fitness and pathogenesis. PLoS Pathog 2014;10:e1004077.

Walls AC, Park YJ, Tortorici MA, Wall A, McGuire AT, Veesler D. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell 2020;181:281-92.

Li W, Moore MJ, Vasilieva N, Sui J, Wong SK, Berne MA, et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature 2003;426:450-4.

Yuki K, Fujiogi M, Koutsogiannaki S. COVID-19 pathophysiology: A review. Clin Immunol 2020;215:108427.

Tai W, He L, Zhang X, Pu J, Voronin D, Jiang S, et al. Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: Implication for development of RBD protein as a viral attachment inhibitor and vaccine. Cell Mol Immunol 2020;17:613-20.

Marshall JS, Warrington R, Watson W, Kim HL. An introduction to immunology and immunopathology. Allergy Asthma Clin Immunol 2018;14:1-10.

Turvey SE, David HB. Innate immunity. J Allergy Clin Immunol 2010;125:S24-32.

O’Connell P, Aldhamen YA. Systemic innate and adaptive immune responses to SARS-CoV-2 as it relates to other coronaviruses. Hum Vaccines Immunother 2020;16:2980-91.

Uthaisangsook S, Day NK, Bahna SL, Good RA, Haraguchi S. Innate immunity and its role against infections. Ann Allergy Asthma Immunol 2002;88:253-65.

Gong T, Liu L, Jiang W, Zhou R. DAMP-sensing receptors in sterile inflammation and inflammatory diseases. Nat Rev Immunol 2020;20:95-112.

Roers A, Björn H, Hornung V. Recognition of endogenous nucleic acids by the innate immune system. Immunity 2016;44:739-54.

Kikkert M. Innate immune evasion by human respiratory RNA viruses. J Innate Immun 2020;12:4-20.

Larenas-Linnemann D, Rodríguez-Pérez N, Arias-Cruz A, Blandón- Vijil MV, Del Río-Navarro BE, Estrada-Cardona A, et al. Enhancing innate immunity against virus in times of COVID-19: Trying to untangle facts from fictions. World Allergy Organ J 2020;13:100476.

Taefehshokr N, Taefehshokr S, Hemmat N, Heit B. Covid-19: Perspectives on innate immune evasion. Front Immunol 2020;11:580641.

Martin TR, Mark MW, Ivan Z, Richard U. Targeting innate immunity by blocking CD14: Novel approach to control inflammation and organ dysfunction in COVID-19 illness. EBioMedicine 2020;57:102836.

Carty M, Coralie G, Andrew GB. Detection of viral infections by innate immunity. Biochem Pharmacol 2020;183:114316.

Shibabaw T, Meseret DM, Banchamlak T, Birhanu A. Role of IFN and complements system: Innate immunity in SARS-CoV-2. J Inflamm Res 2020;13:507.

Fitzgerald KA, Jonathan CK. Toll-like receptors and the control of immunity. Cell 2020;180:1044-66.

Onofrio L, Michele C, Gaetano F, Vincenzo M, De Placido S, Buonerba C. Toll-like receptors and COVID-19: A two-faced story with an exciting ending. Future Sci OA 2020;6:FSO605.

Li G, Fan Y, Lai Y, Han T, Li Z, Zhou P, et al. Coronavirus infections and immune responses. J Med Virol 2020;92:424-32.

Risitano AM, Mastellos DC, Huber-Lang M, Yancopoulou D, Garlanda C, Ciceri F, et al. Complement as a target in COVID-19? Nat Rev Immunol 2020;20:343-4.

Zhou Y, Lu K, Pfefferle S, Bertram S, Glowacka I, Drosten C, et al. A single asparagine-linked glycosylation site of the severe acute respiratory syndrome coronavirus spike glycoprotein facilitates inhibition by mannose-binding lectin through multiple mechanisms. J Virol 2010;84:8753-64.

Dunkelberger JR, Song WC. Complement and its role in innate and adaptive immune responses. Cell Res 2010;20:34-50.

Gralinski LE, Sheahan TP, Morrison TE, Menachery VD, Jensen K, Leist SR, et al. Complement activation contributes to severe acute respiratory syndrome coronavirus pathogenesis. MBio 2018;9:e01753-18.

Martinez FO, Combes TW, Orsenigo F, Gordon S. Monocyte activation in systemic Covid-19 infection: Assay and rationale. EBioMedicine 2020;59:102964.

Kaplanski G. Interleukin‐18: Biological properties and role in disease pathogenesis. Immunol Rev 2018;281:138-53.

Cavalcante-Silva LH, Carvalho DC, de Almeida Lima E, Galvão JG, de França da Silva JS, de Sales-Neto JM, et al. Neutrophils and COVID-19: The road so far. Int Immunopharmacol 2021;90:107233.

Taefehshokr N, Taefehshokr S, Hemmat N, Heit B. Covid-19: Perspectives on innate immune evasion. Front Immunol 2020;11:580641.

Arcanjo A, Logullo J, Menezes CC, de Souza Carvalho Giangiarulo TC, dos Reis MC, de Castro GM, et al. The emerging role of neutrophil extracellular traps in severe acute respiratory syndrome coronavirus 2 (COVID-19). Sci Rep 2020;10:1-11.

van Eeden C, Khan L, Osman MS, Tervaert JW. Natural killer cell dysfunction and its role in COVID-19. Int J Mol Sci 2020;21:6351.

National Research Project for SARS, Beijing Group. The involvement of natural killer cells in the pathogenesis of severe acute respiratory syndrome. Am J Clin Pathol 2004;121:507-11.

Zheng M, Gao Y, Wang G, Song G, Liu S, Sun D, et al. Functional exhaustion of antiviral lymphocytes in COVID-19 patients. Cell Mol Immunol 2020;17:533-5.

Borges RC, Hohmann MS, Borghi SM. Dendritic cells in COVID-19 immunopathogenesis: Insights for a possible role in determining disease outcome. Int Rev Immunol 2021;40:108-25.

Campana P, Parisi V, Leosco D, Bencivenga D, Ragione FD, Borriello A. Dendritic cells and SARS-CoV-2 infection: Still an unclarified connection. Cells 2020;9:2046.

Fensterl V, Saurabh C, Ganes CS. No love lost between viruses and interferons. Ann Rev Virol 2015;2:549-72.

Wang BX, Eleanor NF. Global virus outbreaks: Interferons as 1st responders. Semin Immunol 2019;43:101300.

Chen G, Wu D, Guo W, Cao Y, Huang D, Wang H, et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Investig 2020;130:2620-9.

Harapan H, Itoh N, Yufika A, Winardi W, Keam S, Te H, et al. Coronavirus disease 2019 (COVID-19): A literature review. J Infect Public Health 2020;13:667-73.

CDC COVID-19 Response Team. Severe outcomes among patients with coronavirus disease 2019 (COVID-19)-United States, February 12-March 16, 2020. MMWR Morb Mortal Wkly Rep 2020;69:343.

Huang C, Wang Y, Li X, Ren L, Zhao J, Hu T, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395:497-506.

Dogra P, Ruiz-Ramírez J, Sinha K, Butner JD, Peláez MJ, Rawat M, et al. Innate immunity plays a key role in controlling viral load in COVID-19: Mechanistic insights from a whole-body infection dynamics model. ACS Pharmacol Transl Sci 2020;4:248-65.

Totura AL, Ralph SB. SARS coronavirus pathogenesis: Host innate immune responses and viral antagonism of interferon. Curr Opin Virol 2012;2:264-75.

Merad M, Jerome CM. Pathological inflammation in patients with COVID-19: A key role for monocytes and macrophages. Nat Rev Immunol 2020;20:355-62.

Amor S, Blanco LF, Baker D. Innate immunity during SARS‐CoV‐2: Evasion strategies and activation trigger hypoxia and vascular damage. Clin Exp Immunol 2020;202:193-209.

Xia X. Extreme genomic CpG deficiency in SARS-CoV-2 and evasion of host antiviral defense. Mol Biol Evol 2020;37:2699-705.

Decroly E, Debarnot C, Ferron F, Bouvet M, Coutard B, Imbert I, et al. Crystal structure and functional analysis of the SARS-coronavirus RNA cap 2’-O-methyltransferase nsp10/nsp16 complex. PLoS Pathog 2011;7:e1002059.

Taylor JK, Coleman CM, Postel S, Sisk JM, Bernbaum JE, Venkataraman T, et al. Severe acute respiratory syndrome coronavirus ORF7a inhibits bone marrow stromal antigen 2 virion tethering through a novel mechanism of glycosylation interference. J Virol 2015;89:11820-33.

Totura AL, Ralph SB. SARS coronavirus pathogenesis: Host innate immune responses and viral antagonism of interferon. Curr Opin Virol 2012;2:264-75.

Bouayad A. Innate immune evasion by SARS‐CoV‐2: Comparison with SARS‐CoV. Rev Med Virol 2020;30:1-9.

Lee SJ, Rudragouda C, Thirumala-Devi K. Coronaviruses: Innate immunity, inflammasome activation, inflammatory cell death, and cytokines. Trends Immunol 2020;41:1083-99.

Published

06-09-2021

How to Cite

NANDAGOPAL, M., A. BALAKRISHNAN, and C. PADHIAR. “TRINITY OF SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS-2: ORIGIN, GENOTYPE, PHENOTYPE, AND IMMUNE RESPONSE IN CORONAVIRUS DISEASE-2019”. Asian Journal of Pharmaceutical and Clinical Research, vol. 14, no. 9, Sept. 2021, pp. 28-36, doi:10.22159/ajpcr.2021.v14i9.42363.

Issue

Section

Review Article(s)